Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile
Datamonitor, April 2011, Pages: 63
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Mitsubishi Tanabe's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Your key questions answered
- Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
- See how the launch of pipeline products will generate modest growth and offset expiring product declines for the company
ABOUT THIS PROFILE
- PharmaVitae Explorer database
- Chapter structure
-- Quarterly update
-- Company introduction
-- Company sales
-- Company financials
-- Key products and competitors
- Data sourcing
-- Analyst consensus
EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2003–15
- Operating costs and profit analysis
- Mitsubishi Tanabe: PharmaVitae forecasts at a glance
- Strategic insight
-- 2007: Tanabe and Mitsubishi merge amid a wave of Japanese consolidation
-- 2009–15: greater scale but slow growth
- SWOT analysis
-- Strengths
-- Weaknesses
-- Opportunities
-- Threats
QUARTERLY UPDATE
- Latest prescription pharma product news
-- Q2 2010
-- Q1 2010
-- Q4 2009
-- Q3 2009
- Latest corporate news
-- Q2 2010
-- Q1 2010
-- Q3 2009
- Future product milestones
COMPANY INTRODUCTION
- Key findings
- Background
- M&A history
-- Merger of Mitsubishi Pharma and Tanabe Seiyaku
-- M&A history: Mitsubishi Pharma
-- M&A history: Tanabe Seiyaku
-- M&A strategy
- Current corporate structure
-- Pharmaceuticals segment
-- Other business segment
COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2003–15
- Product analysis
-- Product analysis, 2003–09
-- Product analysis, 2009–15
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
-- Explanation of launch/core/expiry analysis
-- Launch analysis, 2009–15
-- Core analysis, 2009–15
-- Expiry analysis, 2009–15
-- Launch/core/expiry configuration, 2009–15
- Molecule type analysis
- Externalization analysis
COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
- Operating costs and profit analysis
-- Operating costs and profit analysis, 2003–09
-- Operating cost ratio and profit margin analysis, 2003–09
-- Operating cost ratio and profit margin analysis, 2009–15
-- Operating costs and profit analysis, 2009–15
APPENDIX
- References
TABLES
Table: Mitsubishi Tanabe: PharmaVitae forecasts at a glance
Table: Mitsubishi Tanabe upcoming milestones
Table: Mitsubishi Tanabe product portfolio overview ($m), 2003–09
Table: Mitsubishi Tanabe product portfolio overview ($m), 2009–15
Table: Mitsubishi Tanabe prescription pharmaceutical sales, by therapy area ($m), 2009–15
Table: Mitsubishi Tanabe prescription pharmaceutical sales, by geographic region ($m), 2009–15
Table: Mitsubishi Tanabe launch portfolio overview ($m), 2009–15
Table: Mitsubishi Tanabe core portfolio overview ($m), 2009–15
Table: Mitsubishi Tanabe expiry portfolio overview ($m), 2009–15
Table: Mitsubishi Tanabe prescription pharmaceutical sales, by molecule type ($m), 2009–15
Table: Mitsubishi Tanabe prescription pharmaceutical sales, by source ($m), 2009–15
Table: Total Mitsubishi Tanabe sales, by business unit ($m), 2003–09
Table: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2003–09
Table: Mitsubishi Tanabe operating cost ratio analysis (percentage of total revenues), 2003–09
Table: Mitsubishi Tanabe operating cost ratio analysis (% of total revenues), 2009–15
Table: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2009–15
FIGURES
Figure: The PharmaVitae Explorer
Figure: Mitsubishi Tanabe prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2003–15
Figure: Japan pharma peer set, company ranking by prescription pharmaceutical sales ($m), 2003–15
Figure: Mitsubishi Tanabe prescription pharmaceutical sales, by source ($m), 2003–15
Figure: Mitsubishi Tanabe SWOT analysis
Figure: M&A/divestment history
Figure: Current corporate structure
Figure: Mitsubishi Tanabe prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15
Figure: Key product sales ($m), 2003–15
Figure: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2003–09
Figure: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2009–15
Figure: Mitsubishi Tanabe prescription pharmaceutical sales, by therapy area ($m), 2003–15
Figure: Mitsubishi Tanabe prescription pharmaceutical sales, by geographic region ($m), 2003–15
Figure: Mitsubishi Tanabe launch/core/expiry configuration ($m), 2009–15
Figure: Mitsubishi Tanabe prescription pharmaceutical sales, by molecule type ($m), 2003–15
Figure: Mitsubishi Tanabe prescription pharmaceutical sales, by source ($m), 2003–15
Figure: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2003–15
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
